Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?-Reference-Cited by-同舟云学术

Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?

Published:2023-06 Issue:6 Volume:83 Page:481-483
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Varatharajan Abirramy,Olivier Timothée,Prasad Vinay

Funder

Arnold Ventures

Publisher

Elsevier BV

Subject

Urology

Reference20 articles.

1. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study;Hofman;Lancet,2020

2. 68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli?;Lengana;Clin Genitourin Cancer,2018

3. PSMA PET-CT improves staging;Killock;Nat Rev Clin Oncol,2020

4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®). Prostate cancer version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

5. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Parker;Ann Oncol,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stellenwert der lokalen Therapien beim oligometastasierten, hormonsensitiven Prostatakarzinom;Die Urologie;2024-02-08

2. Prognostic Value of PSMA PET/CT in Prostate Cancer;Seminars in Nuclear Medicine;2024-01

3. The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2023-11-08

4. EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer;Cancers;2023-10-16

5. Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions;Current Opinion in Urology;2023-09-11